Dr. Robert A. Naismith, MD
Urology (Urology Physician)
601 Texan Trl, Ste. 100
Corpus Christi, TX 78411
Who else practices at this address →
Nueces County includes mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 784
Licensed in Texas since 1994, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: University of Texas Southwestern Medical School at Dallas
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
TX license J6615 (first issued 1994; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Christus Spohn Hospital Corpus Christi Corpus Christi, TX
- Corpus Christi Medical Center,the Corpus Christi, TX
Medical groups
- Corpus Christi Urology Group PLLC (12 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 784
- Services billed
- 7,204
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Manual urinalysis test with examination using microscope, non-automated | 1,235 | 656 |
| Ultrasound measurement of bladder capacity after voiding | 649 | 417 |
| Established patient office or other outpatient visit, 30-39 minutes | 629 | 398 |
| Established patient office or other outpatient visit, 20-29 minutes | 554 | 412 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 183 | 24 |
| Insertion of needle into vein for collection of blood sample | 177 | 145 |
| Psa (prostate specific antigen) measurement, total | 172 | 139 |
| Diagnostic exam of bladder and urethra using an endoscope | 170 | 156 |
| New patient office or other outpatient visit, 45-59 minutes | 83 | 83 |
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 83 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 13 payments worth $395 in total to this clinician.
| Sumitomo Pharma America, Inc. | $151 |
|---|---|
| Agiliti Surgical, Inc. | $97.32 |
| AbbVie Inc. | $93.34 |
| Boston Scientific Corporation | $31.64 |
| Myriad Genetic Laboratories, Inc. | $21.75 |
| Food and Beverage | $395 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $155,179 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After …
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.